Explore the Agenda
7:30 am Check In & Morning Coffee
8:20 am Chair’s Opening Remarks
Advances in European Precision Medicine Trials & Adoption Initiatives Enabling Transformative Patient Selection & Real-World Monitoring Impact
8:30 am The Rise of Precision Medicine & Diagnostics
- An introduction to BIVDA, BIVDA working parties, and how BIVDA is supporting the delivery of the NHS 10-year plan and the Government’s Life Science Strategy
- The role diagnostics will play in delivering the NHS 3 shifts (Hospital to Community, Analogue to Digital, Treatment to Prevention)
- Creating a roadmap from innovation to adoption in the NHS
8:50 am Session Reserved for Foundation Medicine
Presentation details to be announced
9:20 am Liquid Biopsy in the NHS: Where Are We Now & Where Do We Need to Be
- The lung cancer “liquid first” circulating tumour DNA pilot showed the feasibility of a national service: which is cost-effective and improves outcomes
- This led to a commissioned service in this setting and in breast cancer patients becoming resistant to treatment
- Future use cases include ctDNA as a marker of minimal residual disease to both escalate and de-escalate treatment following surgery or curative radiotherapy
- Barriers remain, including setting up “business as usual” services and educating the workforce in interpreting and using these new technologies
9:40 am Transforming Patient Access in Cancer Care: A New Collaborative Era With Roche
Presentation details to be announced
10:10 am Morning Break & Structured Networking
Fuelling Innovation in Novel Endpoints with Best Practices in Digital Pathology & Liquid Biopsy for Early Detection & Patient Enrolment
11:10 am Session Reserved for Thermo Fisher Scientific
Presentation details to be announced
11:40 am Liquid Biopsy Enabling Precision Oncology Clinical Trials
- Defining ctDNA guided clinical trial designs and assay performance requirements for each
- Showcasing ctDNA as a key secondary endpoint of th e TRIDENT-1 clinical trial, a case study discussion
- Partnering on the development of a WGS MRD distributed kit
12:00 pm Discover How SOPHiA GENETICS is Empowering Pharma Companies to Advance Precision Medicine with Next-Generation Genomics Solutions, Improving Patient Access to Innovative Therapies With SOPHiA GENETICS
Presentation details to be announced
12:30 pm From Bench to Bedside: Ensuring Adoption of Novel Clinical Biomarkers in Bladder Cancer
- Understanding drivers and barriers for the adoption of biomarkers in a new disease area
- Sharing J&Js approach to market shaping through agility and partnerships
- Future perspectives on how to manage adoption in the evolving landscape and new CDx modalities, such as AI
1:00 pm Session Reserved for Guardant Health
Presentation details to be announced
1:30 pm Lunch Break & Dedicated 1-to-1 Networking
1:30 pm Lunch & Learn Hosted By Foresight Diagnostics
By Invitation Only
TRACK A: Biomarker Discovery & Translation
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
TRACK A: Biomarker Discovery & Translation
Leveraging Dynamic Oncology Biomarkers for Real-Time Stratification & Evidence-Based Clinical Decisions
2:30 pm Interrogating Publicly Available Datasets for Biomarker Discovery & Prioritisation
Chief Scientific Officer, Step Pharma
- Presenting a worked example of how data from human cell lines and primary tumours can be leveraged to identify biomarker of response to a compound currently in clinical development
- Discussing biomarker complexity as a consideration for clinical development
2:50 pm Strategies for Preserving Valuable Biomarkers in Blood
Medical Affairs Manager (Europe, Middle East, & Africa), BD Medical Essentials, Specimen Management
- Addressing logistical challenges in clinical trials for blood sample processing
- Implementing solutions to stabilise biomarkers at collection and simplify workflows
3:00 pm From Liquid Biopsy to Dynamic Monitoring: ctDNA Empowering Cancer Treatment With Burning Rock Biotech
Presentation details to be announced
3:30 pm Biomarkers in ADCs Light & Shade
Chief Medical Officer, Corbus Pharmaceuticals
- Why we love biomarkers
- Why we should be more careful
- Some brilliance for Netin-4 targeted ADCs and some dullness
3:50 pm Session Reserved for BioIVT
Presentation details to be announced
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
4:20 pm Afternoon Break & Dedicated 1-to-1 Networking
TRACK A: Biomarker Discovery & Translation
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
TRACK A: Biomarker Discovery & Translation
Enhancing Clinical Planning with Reliable Biomarker Management & Pre-Analytics for Scalable Clinical Outcomes
4:50 pm Panel Discussion: Advancing Sample Management & Pre-Analytic Workflows for Robust, Reproducible Clinical Outcomes
Director, Clinical Biomarkers, Moderna
Executive Director, Head Biomarker Operations, GlaxoSmithKline
- How can early integration of a global-ready sample and biomarker strategy into clinical design reduce downstream risk of sample or data variability?
- What are the key approaches to harmonizing pre-analytical workflows, and how can they be controlled across multi-site operations?
- What innovations in digital tools are facilitating end-to-end integrity and reproducibility?
- How are sponsors ensuring consistency in biospecimen handling when working across multiple CROs or laboratory partners?
- What level of collaboration between translational scientists, clinicians, and data teams is needed to ensure biomarker hypotheses remain viable throughout trial execution?
5:20 pm Getting Laboratories Off the Critical Path
Executive Director, Head Biomarker Operations, GlaxoSmithKline
- Thinking digital – how can we plan better and reduce handoffs of data and requirements
- How to keep track of the geopolitical changes in requirements
- Managing pre-analytics should not be left to chance!
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption